In 2021, semaglutides weight-loss brand Wegovy (weekly injectable) was approved for obesity, followed by tirzepatide (Mounjaro) for diabetes (2022) and Zepbound (tirzepatide for obesity) in late 2023
This underscores the role of nanomedicine in enhancing the anti-tumor bioactivity and bioavailability of green tea polyphenols (142)
Semaglutide is FDA-approved for weight management (Wegovy) and type 2 diabetes (Ozempic)
Personalization, Genetic Insights, and Treatment Customization Neither Remedy Meds nor Henry Meds currently incorporate genetic testing for GLP-1 response predisposition into standard intake workflows
Okeleji LO, Hamed MA, Jegede AI, Oyovwi MO, Ajayi AF (2025) Protective effects of coenzyme Q10 against trihexyphenidyl-induced testicular oxidative damage: modulation of antioxidant enzymes, inflammatory markers, hormonal and steroidogenic pathways in rats
Cell Host Microbe 31, 288304.e8